Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer - Cancer Currents Blog

National Cancer Institute sent this bulletin at 01/03/2024 10:56 AM EST

Having trouble viewing this email? View it as a Web page.

Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer
01/03/2024
	FDA approved toripalimab (Loqtorz) based on the results of a large clinical trial showing that, when added to chemotherapy, the drug extended survival in people with nasopharyngeal cancer that returned after initial treatment or spread in the body.

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.